Rhizopus

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Retrieved on: 
Mittwoch, August 30, 2023
Marketing, National Institute of Allergy and Infectious Diseases, COVID-19, Urinary tract infection, Infection, Research, Bangladesh Technical Education Board, Incidence, Tafenoquine, Oxidative stress, Patent, Patient, Disease, Mouse, Mortality, Ageing, NIAID, FDA, NIH, Fluconazole, Malaria, Pharmaceutical industry, Rhizopus

Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market

Key Points: 
  • Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market
    WASHINGTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced the journal, New Microbes and New Infections , has published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity, including against Candida spp.
  • in cell culture, and decreases fungal burden in the lungs in an invasive pulmonary model of Rhizopus in mice.
  • 60P was recently awarded a U.S. patent covering tafenoquine for treatment of COVID-19 and other lung infections.
  • “A substantial unmet need exists for clinical therapies that treat and prevent life-threatening fungal infections,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow.

Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use

Retrieved on: 
Montag, Juni 12, 2023
Research, Technology, Infectious Diseases, Other Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, EUA, UDM, Hair, Infection, Bachelor, BMB, Allergy, Workflow, RPP, Culture, SARS-CoV-2, Software, Pneumocystis jirovecii, COVID-19, Eye, Aspergillus, Histoplasma capsulatum, CE marking, PCR, Nomenclature codes, Immunochemistry, Emergency Use Authorization, Federal Food, Drug, and Cosmetic Act, Panel, Coccidioides, RSV, RUO, Patient, Laboratory, Autoimmune disease, Molecular Probes, IVD, Growth, GPP, Immunodeficiency, Diagnosis, FDA, Mucor, Virus, Vaccine, Rhizopus, Applied Spectral Imaging, Rhizomucor, Fusarium, Cunninghamella, Cryptococcus

The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.

Key Points: 
  • The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.
  • Applied BioCode’s Fungal Panel is intended for research use only and may be used in infectious disease research or pharmaceutical development.
  • “Applied BioCode is thrilled to announce our first release of an RUO panel under our new product strategy.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.